Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
ACAD's Cash to Debt is ranked higher than
98% of the 858 Companies
in the Global Biotechnology industry.

( Industry Median: 68.31 vs. ACAD: No Debt )
Ranked among companies with meaningful Cash to Debt only.
ACAD' s 10-Year Cash to Debt Range
Min: 5.56  Med: 137.83 Max: 98090
Current: No Debt
5.56
98090
Equity to Asset 0.93
ACAD's Equity to Asset is ranked higher than
91% of the 616 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. ACAD: 0.93 )
Ranked among companies with meaningful Equity to Asset only.
ACAD' s 10-Year Equity to Asset Range
Min: -2.13  Med: 0.77 Max: 0.98
Current: 0.93
-2.13
0.98
Interest Coverage No Debt
ACAD's Interest Coverage is ranked higher than
96% of the 385 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. ACAD: No Debt )
Ranked among companies with meaningful Interest Coverage only.
ACAD' s 10-Year Interest Coverage Range
Min: 9999.99  Med: 10000.00 Max: 9999.99
Current: No Debt
F-Score: 2
Z-Score: 105.83
M-Score: -1.20
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -196466.18
ACAD's Operating margin (%) is ranked lower than
99% of the 675 Companies
in the Global Biotechnology industry.

( Industry Median: -71.95 vs. ACAD: -196466.18 )
Ranked among companies with meaningful Operating margin (%) only.
ACAD' s 10-Year Operating margin (%) Range
Min: -77691.67  Med: -566.79 Max: 35.82
Current: -196466.18
-77691.67
35.82
Net-margin (%) -195448.53
ACAD's Net-margin (%) is ranked lower than
99% of the 675 Companies
in the Global Biotechnology industry.

( Industry Median: -68.66 vs. ACAD: -195448.53 )
Ranked among companies with meaningful Net-margin (%) only.
ACAD' s 10-Year Net-margin (%) Range
Min: -77062.5  Med: -553.89 Max: 35.93
Current: -195448.53
-77062.5
35.93
ROE (%) -43.40
ACAD's ROE (%) is ranked lower than
58% of the 775 Companies
in the Global Biotechnology industry.

( Industry Median: -30.76 vs. ACAD: -43.40 )
Ranked among companies with meaningful ROE (%) only.
ACAD' s 10-Year ROE (%) Range
Min: -138.68  Med: -69.63 Max: 72.43
Current: -43.4
-138.68
72.43
ROA (%) -41.42
ACAD's ROA (%) is ranked lower than
63% of the 864 Companies
in the Global Biotechnology industry.

( Industry Median: -26.75 vs. ACAD: -41.42 )
Ranked among companies with meaningful ROA (%) only.
ACAD' s 10-Year ROA (%) Range
Min: -78.95  Med: -59.16 Max: 34.38
Current: -41.42
-78.95
34.38
ROC (Joel Greenblatt) (%) -12915.41
ACAD's ROC (Joel Greenblatt) (%) is ranked lower than
89% of the 833 Companies
in the Global Biotechnology industry.

( Industry Median: -365.20 vs. ACAD: -12915.41 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ACAD' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -21643.52  Med: -1912.22 Max: 2028.76
Current: -12915.41
-21643.52
2028.76
Revenue Growth (3Y)(%) -100.00
ACAD's Revenue Growth (3Y)(%) is ranked lower than
90% of the 411 Companies
in the Global Biotechnology industry.

( Industry Median: 0.30 vs. ACAD: -100.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ACAD' s 10-Year Revenue Growth (3Y)(%) Range
Min: -100  Med: -34.80 Max: 73.1
Current: -100
-100
73.1
EBITDA Growth (3Y)(%) 30.70
ACAD's EBITDA Growth (3Y)(%) is ranked higher than
84% of the 432 Companies
in the Global Biotechnology industry.

( Industry Median: -4.40 vs. ACAD: 30.70 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ACAD' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -42.6  Med: -21.90 Max: 30.7
Current: 30.7
-42.6
30.7
EPS Growth (3Y)(%) 29.20
ACAD's EPS Growth (3Y)(%) is ranked higher than
84% of the 420 Companies
in the Global Biotechnology industry.

( Industry Median: -6.80 vs. ACAD: 29.20 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ACAD' s 10-Year EPS Growth (3Y)(%) Range
Min: -55.3  Med: -10.55 Max: 111.5
Current: 29.2
-55.3
111.5
» ACAD's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

ACAD Guru Trades in Q3 2014

Paul Tudor Jones 10,748 sh (New)
Ron Baron 502,100 sh (+14.90%)
Andreas Halvorsen 4,324,890 sh (-9.10%)
Steven Cohen 925,000 sh (-14.51%)
» More
Q4 2014

ACAD Guru Trades in Q4 2014

Steven Cohen 1,018,600 sh (+10.12%)
Andreas Halvorsen 2,956,266 sh (unchged)
Paul Tudor Jones Sold Out
Ron Baron 497,530 sh (-0.91%)
Andreas Halvorsen 2,956,266 sh (-31.65%)
» More
Q1 2015

ACAD Guru Trades in Q1 2015

Louis Moore Bacon 80,000 sh (New)
Steven Cohen 2,247,300 sh (+120.63%)
Ron Baron 607,100 sh (+22.02%)
Andreas Halvorsen Sold Out
» More
Q2 2015

ACAD Guru Trades in Q2 2015

Paul Tudor Jones 18,969 sh (New)
Ron Baron 639,100 sh (+5.27%)
Louis Moore Bacon Sold Out
Steven Cohen 1,347,256 sh (-40.05%)
» More
» Details

Insider Trades

Latest Guru Trades with ACAD

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 434.78
ACAD's Forward P/E is ranked lower than
95% of the 164 Companies
in the Global Biotechnology industry.

( Industry Median: 22.73 vs. ACAD: 434.78 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 15.01
ACAD's P/B is ranked lower than
87% of the 751 Companies
in the Global Biotechnology industry.

( Industry Median: 4.08 vs. ACAD: 15.01 )
Ranked among companies with meaningful P/B only.
ACAD' s 10-Year P/B Range
Min: 0.48  Med: 4.22 Max: 16.77
Current: 15.01
0.48
16.77
P/S 56607.53
ACAD's P/S is ranked lower than
179% of the 604 Companies
in the Global Biotechnology industry.

( Industry Median: 10.19 vs. ACAD: 56607.53 )
Ranked among companies with meaningful P/S only.
ACAD' s 10-Year P/S Range
Min: 0  Med: 29.87 Max: 56607.53
Current: 56607.53
0
56607.53
Current Ratio 14.11
ACAD's Current Ratio is ranked higher than
85% of the 833 Companies
in the Global Biotechnology industry.

( Industry Median: 4.15 vs. ACAD: 14.11 )
Ranked among companies with meaningful Current Ratio only.
ACAD' s 10-Year Current Ratio Range
Min: 2.27  Med: 5.25 Max: 46.41
Current: 14.11
2.27
46.41
Quick Ratio 14.11
ACAD's Quick Ratio is ranked higher than
86% of the 833 Companies
in the Global Biotechnology industry.

( Industry Median: 4.01 vs. ACAD: 14.11 )
Ranked among companies with meaningful Quick Ratio only.
ACAD' s 10-Year Quick Ratio Range
Min: 2.27  Med: 5.25 Max: 46.41
Current: 14.11
2.27
46.41
Days Sales Outstanding 8.00
ACAD's Days Sales Outstanding is ranked higher than
92% of the 568 Companies
in the Global Biotechnology industry.

( Industry Median: 62.77 vs. ACAD: 8.00 )
Ranked among companies with meaningful Days Sales Outstanding only.
ACAD' s 10-Year Days Sales Outstanding Range
Min: 239.08  Med: 1585.63 Max: 2932.17
Current: 8
239.08
2932.17

Valuation & Return

vs
industry
vs
history
Price/Net Cash 15.27
ACAD's Price/Net Cash is ranked lower than
72% of the 448 Companies
in the Global Biotechnology industry.

( Industry Median: 7.71 vs. ACAD: 15.27 )
Ranked among companies with meaningful Price/Net Cash only.
ACAD' s 10-Year Price/Net Cash Range
Min: 0.69  Med: 4.37 Max: 19.49
Current: 15.27
0.69
19.49
Price/Net Current Asset Value 15.15
ACAD's Price/Net Current Asset Value is ranked lower than
74% of the 537 Companies
in the Global Biotechnology industry.

( Industry Median: 6.85 vs. ACAD: 15.15 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
ACAD' s 10-Year Price/Net Current Asset Value Range
Min: 0.66  Med: 4.14 Max: 18.17
Current: 15.15
0.66
18.17
Price/Tangible Book 15.03
ACAD's Price/Tangible Book is ranked lower than
83% of the 693 Companies
in the Global Biotechnology industry.

( Industry Median: 5.31 vs. ACAD: 15.03 )
Ranked among companies with meaningful Price/Tangible Book only.
ACAD' s 10-Year Price/Tangible Book Range
Min: 0.63  Med: 3.97 Max: 16.49
Current: 15.03
0.63
16.49
Earnings Yield (Greenblatt) (%) -3.72
ACAD's Earnings Yield (Greenblatt) (%) is ranked higher than
59% of the 822 Companies
in the Global Biotechnology industry.

( Industry Median: -6.30 vs. ACAD: -3.72 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ACAD' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -4.25  Med: 71.70 Max: 51153
Current: -3.72
-4.25
51153

Analyst Estimate

Dec15 Dec16 Dec17
Revenue(Mil) 0 132 381
EPS($) -1.62 -0.19 1.11
EPS without NRI($) -1.62 -0.19 1.11

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:DR6.Germany,
ACADIA Pharmaceuticals Inc was incorporated in Vermont in 1993 as Receptor Technologies, Inc. The Company reincorporated in Delaware in 1997. It is a biopharmaceutical Company engaged in the development and commercialization of small molecule drugs for the treatment of central nervous system disorders. It has four product candidates in clinical development led by pimavanserin, which is in Phase III development as a potential first-in-class treatment for Parkinsons disease psychosis. Pimavanserin is a new chemical entity that the Company discovered and has advanced to Phase III development as a potential first-in-class treatment for Parkinsons disease psychosis. Parkinsons disease psychosis is a debilitating disorder that develops in up to 60 percent of patients with Parkinsons disease. The Company has completed a Phase II trial with pimavanserin as a co-therapy in schizophrenia and has established plans for a future Phase II feasibility study to explore the use of pimavanserin as a treatment for Alzheimers disease psychosis. In collaboration with Allergan, it has discovered and is developing small molecule product candidates for the treatment of chronic pain. Chronic pain is a common form of persistent pain that may be related to a number of medical conditions and is often resistant to treatment. Allergan has conducted several Phase II trials in this program and has reported preliminary results, including positive proof-of-concept in a human visceral pain trial and efficacy signals in two chronic pain trials in the areas of fibromyalgia and irritable bowel syndrome. The Company has discovered and, in collaboration with Allergan, is developing a small molecule product candidate for the treatment of glaucoma. Glaucoma is a chronic eye disease and is the second leading cause of blindness in the world. This program has reached Phase I development. ACADIA and R-SAT are company's registered trademarks. The Company faces competition from pharmaceutical and biotechnology companies, as well as numerous academic and research institutions and governmental agencies, both in the United States and abroad. It is subject to federal, state and local laws and regulations governing the use, storage, handling, and disposal of these materials and specified waste products.
» More Articles for ACAD

Headlines

Articles On GuruFocus.com
Andreas Halvorsen Increases Stake in Esperion Therapeutics Jun 29 2015 
Acadia Has Tough Road Ahead With Nuplazid Success Mar 14 2015 
Analysts Remain Bullish on Acadia Pharma Despite Drug Approval Delay Mar 13 2015 
Weekly CFO Sells Highlight: KO, KKD, PIR, NPSP, ACAD Apr 16 2013 
comment on ACAD Mar 02 2013 
ACADIA Pharmaceuticals Reports Second Quarter 2009 Financial Results Aug 05 2009 
ACADIA Pharmaceuticals to Announce Second Quarter 2009 Financial Results on August 5, 2009 Jul 29 2009 
ACADIA Pharmaceuticals Inc. Reports Operating Results (10-Q) May 11 2009 

More From Other Websites
Why Piper Jaffray Is Upgrading Acadia Pharmaceuticals After A 25% Decline Aug 27 2015
Acadia Pharmaceuticals Fell 19% after Reporting 2Q15 Earnings Aug 27 2015
ACADIA Pharmaceuticals upgraded by Piper Jaffray Aug 27 2015
Some Pharma Stocks Trade below All Moving Averages in Early August Aug 25 2015
IBB ETF Pounded by Biotech and Pharma Subgroups in Early August Aug 25 2015
What Are IBB and XBI’s Valuations? Aug 25 2015
ACADIA PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement Aug 21 2015
ACADIA PHARMACEUTICALS INC Financials Aug 15 2015
Why ACADIA Pharmaceuticals (ACAD) Could Be Positioned for a Slump Aug 14 2015
This Undervalued Biotech Company Just Filed For FDA Approval and No One Noticed Aug 11 2015
10-Q for ACADIA Pharmaceuticals, Inc. Aug 08 2015
Acadia Pharma May No Longer Be A Buy Ahead Of NDA Filing Aug 07 2015
Acadia reports 2Q loss Aug 06 2015
Acadia reports 2Q loss Aug 06 2015
Edited Transcript of ACAD earnings conference call or presentation 6-Aug-15 9:00pm GMT Aug 06 2015
ACADIA Pharmaceuticals Inc Earnings Call scheduled for 5:00 pm ET today Aug 06 2015
ACADIA PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition,... Aug 06 2015
ACADIA Pharmaceuticals Reports Second Quarter 2015 Financial Results Aug 06 2015
ACADIA Pharmaceuticals Announces Publication of Data from Its -015 Open Label Safety Study in... Aug 06 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK